8-K Announcements
6Material company update
May 15, 2026·SEC
Material company update
Mar 30, 2026·SEC
Material company update
Mar 27, 2026·SEC
PAVmed Inc.(PAVM)Earnings, Financials & Key Ratios
PAVM•NASDAQ
Price updated Jun 19, 2026
AboutPAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.Show more
- Revenue$71K-97.6%
- EBITDA-$22M+49.9%
- Net Income$401K-99.0%
- EPS (Diluted)-5.63-137.8%
- Gross Margin-354.93%-249.3%
- EBITDA Margin-30564.79%-2014.7%
- Operating Margin-30712.68%-1967.7%
- Net Margin564.79%-57.5%
- ROE5.25%
PAVM Key Insights
PAVmed Inc. (PAVM) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 99 (top 1%)
- ✓Share count reduced 69.2% through buybacks
- ✓Trading at only 0.2x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when PAVM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PAVM Price & Volume
PAVmed Inc. (PAVM) stock price & volume — 10-year historical chart
Loading chart...
PAVM Growth Metrics
PAVmed Inc. (PAVM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-42.68%
TTM1007.02%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-9572.05%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-2086814.25%
Return on Capital
10 Years-864.15%
5 Years-319.07%
3 Years-419.99%
Last Year-227.28%
PAVM Recent Earnings
PAVmed Inc. (PAVM) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 3/12 qtrs (27%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$1.17-69.6%
$0.69
Rev
$22,000-70.3%
$74,000
Q2 2026
Mar 30, 2026Metric
Actual
Est
EPS
$1.05-50.0%
$0.70
Rev
—
$74,000
Q2 2026
Mar 26, 2026Metric
Actual
Est
EPS
$2.05+54.4%
$4.50
Rev
$52,000+108.0%
$25,000
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$8.41-39.9%
$6.01
Rev
$5,000-60.0%
$12,500
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $1.17vs $0.69-69.6% | $22,000vs $74,000-70.3% |
| Q2 2026 | Mar 30, 2026 | $1.05vs $0.70-50.0% | —vs $74,000 |
| Q2 2026 | Mar 26, 2026 | $2.05vs $4.50+54.4% | $52,000vs $25,000+108.0% |
| Q4 2025 | Nov 13, 2025 | $8.41vs $6.01-39.9% | $5,000vs $12,500-60.0% |
Based on last 12 quarters of dataView full earnings history →
PAVM Peer Comparison
PAVmed Inc. (PAVM) competitors in Surgical tools, endoscopy, and robotics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 MGRX | 3.33M | 0.33 | -0.16 | -25.96% | -46.33% | -120.72% | 0.02 | |
 ATEC | 1.33B | 8.81 | -9.18 | 24.95% | -21.07% | -443.09% | 17.21 | |
 GKOS | 7.65B | 130.68 | -39.84 | 32.33% | -34.34% | -26.46% | 0.21 | |
 TMDX | 2.72B | 78.79 | 16.18 | 37.13% | 27.04% | 41.92% | 0.99 | |
 PRCT | 1.24B | 21.72 | -12.63 | 37.22% | -31.82% | -27.7% | 0.14 | |
 MDT | 101.86B | 79.34 | 21.98 | 3.62% | 13% | 9.49% | 0.59 |
Compare PAVM vs Peers
PAVmed Inc. (PAVM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PAVM Income Statement
PAVmed Inc. (PAVM) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 500K | 377K | 2.45M | 3M | 71K | 22.06M |
Revenue Growth % | - | - | - | - | - | -24.6% | 550.4% | 22.15% | -97.63% | 1007.02% |
Cost of Goods Sold | 7.11K | 9.79K | 14.23K | 0 | 585K | 3.61M | 6.42M | 6.04M | 323K | 97.2M |
COGS % of Revenue | - | - | - | - | 117% | 958.62% | 261.83% | 201.6% | 454.93% | - |
Gross Profit | -7.11K▲ 0% | -9.79K▼ 37.7% | -14.23K▼ 45.3% | 0▲ 100.0% | -85K▲ 0% | -3.24M▼ 3708.2% | -3.97M▼ 22.6% | -3.04M▲ 23.3% | -252K▲ 91.7% | -75.14M▲ 0% |
Gross Margin % | - | - | - | - | -17% | -858.62% | -161.83% | -101.6% | -354.93% | -340.55% |
Gross Profit Growth % | -87.45% | -37.69% | -45.31% | 100% | - | -3708.24% | -22.58% | 23.31% | 91.72% | - |
Operating Expenses | 8.03M | 10.56M | 14.3M | 23.35M | 54.31M | 87.85M | 64.83M | 41.44M | 21.55M | 7.98B |
OpEx % of Revenue | - | - | - | - | 10861.6% | 23302.39% | 2643.84% | 1383.77% | 30357.75% | - |
Selling, General & Admin | 5.42M | 6.31M | 7.66M | 12.39M | 34.46M | 60.73M | 48.53M | 36.15M | 17.17B | 23.73B |
SG&A % of Revenue | - | - | - | - | 6892.2% | 16108.22% | 1979.2% | 1207.05% | 24178873.24% | - |
Research & Development | 2.62M | 4.25M | 6.63M | 10.96M | 19.85M | 25.34M | 14.28M | 5.93M | 4.49B | 1.39B |
R&D % of Revenue | - | - | - | - | 3969.4% | 6720.95% | 582.22% | 198.06% | 6326760.56% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 1.78M | 2.02M | -639K | -21.64B | -1000K |
Operating Income | -8.03M▲ 0% | -10.56M▼ 31.5% | -14.3M▼ 35.3% | -23.35M▼ 63.3% | -54.39M▼ 132.9% | -91.09M▼ 67.5% | -68.8M▲ 24.5% | -44.49M▲ 35.3% | -21.81M▲ 51.0% | -8.05B▲ 0% |
Operating Margin % | - | - | - | - | -10878.6% | -24161.01% | -2805.67% | -1485.38% | -30712.68% | -36492.6% |
Operating Income Growth % | -42.18% | -31.48% | -35.33% | -63.35% | -132.94% | -67.46% | 24.47% | 35.33% | 50.98% | - |
EBITDA | -8.03M | -10.55M | -14.28M | -23.33M | -54.17M | -88.63M | -65.86M | -43.29M | -21.7M | -8.05B |
EBITDA Margin % | - | - | - | - | -10833.4% | -23509.28% | -2686.09% | -1445.38% | -30564.79% | -36492.23% |
EBITDA Growth % | -42.14% | -31.47% | -35.32% | -63.35% | -132.2% | -63.62% | 25.69% | 34.27% | 49.87% | -22746.99% |
D&A (Non-Cash Add-back) | 7.11K | 9.79K | 14.23K | 23K | 226K | 2.46M | 2.93M | 1.2M | 105K | 82K |
EBIT | -8.79M | -15.17M | -16.69M | -23.35M | -56.13M | -101.96M | -78.67M | 28.47M | -21.81M | -8.06B |
Net Interest Income | 0 | 0 | 333 | 0 | 0 | -1.11M | -84K | 209K | 8K | 22K |
Interest Income | 0 | 0 | 33K | 53K | 0 | 169K | 505K | 254K | 29K | 42K |
Interest Expense | 724.68K | 2.39M | 32.67K | 53K | 0 | 1.28M | 589K | 45K | 21K | 20K |
Other Income/Expense | -1.49M | -7.61M | -2.97M | -12.54M | -1.73M | -12.15M | -10.47M | 72.91M | 19.34M | 6.97B |
Pretax Income | -9.52M▲ 0% | -18.17M▼ 90.9% | -17.27M▲ 5.0% | -35.89M▼ 107.8% | -56.13M▼ 56.4% | -103.24M▼ 83.9% | -79.26M▲ 23.2% | 28.43M▲ 135.9% | -2.47M▼ 108.7% | -1.09B▲ 0% |
Pretax Margin % | - | - | - | - | -11225.2% | -27384.08% | -3232.59% | 949.15% | -3477.46% | -4918.15% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.92B |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -545.94% |
Net Income | -9.52M▲ 0% | -17.97M▼ 88.8% | -15.93M▲ 11.3% | -34.28M▼ 115.1% | -50.35M▼ 46.9% | -88.98M▼ 76.7% | -64.17M▲ 27.9% | 39.79M▲ 162.0% | 401K▼ 99.0% | -7.01B▲ 0% |
Net Margin % | - | - | - | - | -10069.4% | -23602.92% | -2617.25% | 1328.58% | 564.79% | -31757.09% |
Net Income Growth % | -68.46% | -88.76% | 11.34% | -115.15% | -46.89% | -76.74% | 27.88% | 162% | -98.99% | -9572.05% |
Net Income (Continuing) | -9.52M | -18.17M | -17.27M | -35.89M | -56.13M | -103.24M | -79.26M | 28.43M | -2.47M | -7.01B |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | -161.51K | -814.28K | -2.37M | 17.75M | 20.61M | 29.81M | -4.54M | -11.67M | -14.54M |
EPS (Diluted) | -346.50▲ 0% | -378.78▼ 9.3% | -249.27▲ 34.2% | -327.91▼ 31.5% | -293.92▲ 10.4% | -450.95▼ 53.4% | -274.92▲ 39.0% | 14.88▲ 105.4% | -5.63▼ 137.8% | -443257.23▲ 0% |
EPS Growth % | -75% | -9.32% | 34.19% | -31.55% | 10.36% | -53.43% | 39.04% | 105.41% | -137.83% | -2086814.25% |
EPS (Basic) | -346.50 | -378.78 | -249.27 | -327.91 | -293.92 | -450.95 | -274.92 | 99.15 | -5.63 | - |
Diluted Shares Outstanding | 29.99K | 49.5K | 67.11K | 105.41K | 172.26K | 197.95K | 241.05K | 2.18M | 670.47K | 15.81K |
Basic Shares Outstanding | 29.99K | 49.5K | 67.11K | 105.41K | 172.26K | 197.95K | 241.05K | 322.41K | 670.47K | 15.81K |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
PAVM Balance Sheet
PAVmed Inc. (PAVM) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 1.62M | 8.46M | 6.55M | 18.94M | 82.64M | 43.93M | 24.5M | 2.16M | 2.56M | 7.41M |
Cash & Short-Term Investments | 1.54M | 8.22M | 6.22M | 17.52M | 79.25M | 42.75M | 19.64M | 1.19M | 1.54M | 6.46M |
Cash Only | 1.54M | 8.22M | 6.22M | 17.26M | 77.26M | 39.74M | 19.64M | 1.19M | 1.54M | 6.46M |
Short-Term Investments | 0 | 0 | 0 | 262K | 1.99M | 3M | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 | 200K | 17K | 61K | 18K | 15K | 21K |
Days Sales Outstanding | - | - | - | - | 146 | 16.46 | 9.08 | 2.19 | 77.11 | 0.17 |
Inventory | 0 | 0 | 0 | 855K | 526K | 261K | 539K | 266K | 239K | 0 |
Days Inventory Outstanding | - | - | - | - | 328.19 | 26.36 | 30.64 | 16.08 | 270.08 | 0.24 |
Other Current Assets | 0 | 0 | 34.12K | 507K | 808K | 599K | 3.41M | 0 | 0 | 615K |
Total Non-Current Assets | 16.19K | 36.27K | 692.94K | 837K | 4.34M | 10.05M | 8.62M | 28.5M | 36.26M | 38M |
Property, Plant & Equipment | 16.19K | 36.27K | 0 | 82K | 1.58M | 5.49M | 6.05M | 2.65M | 2.08M | 1.95M |
Fixed Asset Turnover | - | - | - | - | 0.32x | 0.07x | 0.41x | 1.13x | 0.03x | 10.26x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 2.03M | 3.44M | 1.42M | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25.64M | 34.12M | 137.73M |
Other Non-Current Assets | 0 | 0 | 692.94K | 755K | 725K | 1.12M | 1.15M | 208K | 56K | 56K |
Total Assets | 1.64M▲ 0% | 8.5M▲ 418.2% | 7.24M▼ 14.8% | 19.78M▲ 173.2% | 86.98M▲ 339.8% | 53.98M▼ 37.9% | 33.12M▼ 38.6% | 30.66M▼ 7.4% | 38.81M▲ 26.6% | 45.42M▲ 0% |
Asset Turnover | - | - | - | - | 0.01x | 0.01x | 0.07x | 0.10x | 0.00x | 0.53x |
Asset Growth % | 88.38% | 418.18% | -14.78% | 173.16% | 339.76% | -37.94% | -38.65% | -7.42% | 26.59% | 48.55% |
Total Current Liabilities | 2.54M | 10.97M | 11.88M | 20.25M | 7.56M | 41.2M | 54.18M | 35.45M | 14.84M | 3.66M |
Accounts Payable | 864.4K | 1.74M | 2.35M | 2.97M | 3.3M | 2.7M | 1.79M | 657K | 678K | 983K |
Days Payables Outstanding | 44.38K | 64.83K | 60.37K | - | 2.06K | 273.09 | 101.54 | 39.72 | 766.16 | 2.24 |
Short-Term Debt | 0 | 7.9M | 8.14M | 14.96M | 0 | 33.65M | 44.2M | 29.1M | 11.1M | 588K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 656.34M | 0 | 0 |
Other Current Liabilities | 983.6K | 272.43K | 311.63K | 355K | 25K | 10K | 4.12M | -654.83M | 1.97M | 2.09M |
Current Ratio | 0.64x | 0.77x | 0.55x | 0.94x | 10.93x | 1.07x | 0.45x | 0.06x | 0.17x | 2.02x |
Quick Ratio | 0.64x | 0.77x | 0.55x | 0.89x | 10.86x | 1.06x | 0.44x | 0.05x | 0.16x | 2.02x |
Cash Conversion Cycle | - | - | - | - | -1.58K | -230.27 | -61.82 | -21.44 | -418.97 | -1.83 |
Total Non-Current Liabilities | 1.94M | 9.64M | 10.49M | 0 | 0 | 1.85M | 2.96M | 2.25M | 1.68M | 16.77M |
Long-Term Debt | 1.94M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14.9M |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 1.85M | 2.96M | 2.25M | 1.68M | 6.99M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 345K |
Total Liabilities | 4.49M | 10.97M | 11.88M | 20.25M | 7.56M | 43.05M | 57.14M | 37.69M | 16.51M | 20.43M |
Total Debt | 1.94M | 7.9M | 8.14M | 14.96M | 0 | 36.64M | 48.73M | 31.86M | 13.35M | 17.01M |
Net Debt | 409.25K | -319.12K | 1.92M | -2.3M | -77.26M | -3.11M | 29.09M | 30.68M | 11.81M | 10.55M |
Debt / Equity | - | - | - | - | - | 3.35x | - | - | 0.60x | 0.68x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
Interest Coverage | -12.14x | -6.34x | -510.77x | -440.58x | - | -79.59x | -133.57x | 632.71x | -1038.38x | -403006.30x |
Total Equity | -2.85M▲ 0% | -2.48M▲ 13.1% | -4.64M▼ 87.3% | -473K▲ 89.8% | 79.42M▲ 16890.3% | 10.93M▼ 86.2% | -24.02M▼ 319.7% | -7.03M▲ 70.7% | 22.3M▲ 417.1% | 24.99M▲ 0% |
Equity Growth % | -792.71% | 13.07% | -87.31% | 89.8% | 16890.27% | -86.23% | -319.66% | 70.72% | 417.08% | 1021.37% |
Book Value per Share | -94.97 | -50.02 | -69.12 | -4.49 | 461.04 | 55.24 | -99.64 | -3.23 | 33.26 | 1580.82 |
Total Shareholders' Equity | -2.85M | -2.31M | -3.82M | 1.9M | 61.67M | -9.68M | -53.83M | -2.5M | 33.97M | 39.52M |
Common Stock | 14.55K | 27.14K | 40.48K | 64K | 86K | 6K | 9K | 11K | 1K | 6K |
Retained Earnings | -17.91M | -36.99M | -53.71M | -88.28M | -138.91M | -228.17M | -294.43M | -254.97M | -258.73M | -259.03M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | -408K | 0 | 0 | 0 | 0 |
Accumulated OCI | -1.03M | -2.03M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | -161.51K | -814.28K | -2.37M | 17.75M | 20.61M | 29.81M | -4.54M | -11.67M | -14.54M |
PAVM Cash Flow Statement
PAVmed Inc. (PAVM) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -6.61M | -8.79M | -13.36M | -21.91M | -40.59M | -70.98M | -52.04M | -33.55M | -5.21B | -2.62B |
Operating CF Margin % | - | - | - | - | -8118.2% | -18828.91% | -2122.19% | -1120.33% | -7332394.37% | - |
Operating CF Growth % | -48.34% | -32.98% | -52% | -64.06% | -85.23% | -74.88% | 26.69% | 35.52% | -15415.29% | -167188.09% |
Net Income | -9.52M | -18.17M | -17.27M | -35.89M | -56.13M | -103.24M | -79.26M | 28.43M | -2.47B | -7.01B |
Depreciation & Amortization | 7.11K | 9.79K | 14.23K | 23K | 226K | 2.46M | 2.93M | 1.2M | 105M | 20.06M |
Stock-Based Compensation | 1.05M | 1.23M | 1.57M | 2.04M | 15.01M | 19.53M | 11.14M | 6.45M | 1.71B | 182.39M |
Deferred Taxes | -2.36M | 3.7M | 1.83M | 6.5M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 3.66M | 3.1M | 558.6K | 5.33M | 1.87M | 10.98M | 11.56M | -70.14M | -4.55B | -1.74B |
Working Capital Changes | 559.22K | 1.35M | -63.93K | 83K | -1.57M | -716K | 1.59M | 512K | 98K | 400K |
Change in Receivables | 0 | 0 | 0 | 0 | -200K | 183K | -44K | 43K | 3K | -11K |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -85.01K | 872.11K | 613.28K | 501K | 174K | -742K | -918K | -59K | 24K | 613K |
Cash from Investing | -5.3K | -26.61K | -27.2K | -55K | -3.72M | -4.74M | 758K | -16.18M | -31M | -22.02M |
Capital Expenditures | -5.3K | -26.61K | -27.2K | -55K | -1.47M | -1.54M | -242K | -55K | -31K | -47K |
CapEx % of Revenue | - | - | - | - | 293.8% | 408.49% | 9.87% | 1.84% | 43.66% | 0.21% |
Acquisitions | 0 | 0 | 0 | 0 | -2.25M | -3.2M | 0 | -16.48M | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -5.3K | -26.61K | 0 | 0 | 0 | 0 | 1M | 350K | -30.97M | -21.98M |
Cash from Financing | 7.56M | 15.5M | 11.38M | 33.01M | 104.31M | 38.21M | 31.17M | 31.28M | 5.59B | 7.57B |
Debt Issued (Net) | 4.84M | 2M | 5.94M | 16.7M | -14.97M | 35.23M | 9.92M | -531K | 0 | 3.85M |
Equity Issued (Net) | 3.11M | 4.41M | 5.45M | 16.03M | 117.02M | 1.52M | 20.44M | 31.4M | 5.7M | 6.2M |
Dividends Paid | 0 | -7.1K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | -366K | 0 | 0 | 0 | 0 |
Other Financing | -388.63K | 9.1M | 0 | 274K | 2.26M | 1.46M | 810K | 419K | 5.58B | 7.56B |
Net Change in Cash | 949.34K▲ 0% | 6.69M▲ 604.4% | -2M▼ 130.0% | 11.04M▲ 651.1% | 60M▲ 443.6% | -37.51M▼ 162.5% | -20.11M▲ 46.4% | -18.45M▲ 8.2% | 353M▲ 2012.9% | 4.92B▲ 0% |
Free Cash Flow | -6.61M▲ 0% | -8.81M▼ 33.3% | -13.38M▼ 51.8% | -21.97M▼ 64.1% | -42.06M▼ 91.5% | -72.53M▼ 72.4% | -52.28M▲ 27.9% | -33.61M▲ 35.7% | -5.21B▼ 15389.9% | -2.62B▲ 0% |
FCF Margin % | - | - | - | - | -8412% | -19237.4% | -2132.06% | -1122.17% | -7332394.37% | -11891.63% |
FCF Growth % | -47.73% | -33.28% | -51.85% | -64.14% | -91.45% | -72.43% | 27.92% | 35.71% | -15389.9% | -11801.34% |
FCF per Share | -220.52 | -178.06 | -199.46 | -208.42 | -244.17 | -366.39 | -216.87 | -15.44 | -7764.75 | -165980.26 |
FCF Conversion (FCF/Net Income) | 0.69x | 0.49x | 0.84x | 0.64x | 0.81x | 0.80x | 0.81x | -0.84x | -12982.54x | 0.37x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PAVM Key Ratios
PAVmed Inc. (PAVM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | - | - | -127.55% | -196.97% | - | - | 5.25% | -26820.94% |
Return on Invested Capital (ROIC) | - | - | - | - | - | -1368.08% | -800.25% | -232.43% | -56.64% | -17460.32% |
Gross Margin | - | - | - | - | -17% | -858.62% | -161.83% | -101.6% | -354.93% | -340.55% |
Net Margin | - | - | - | - | -10069.4% | -23602.92% | -2617.25% | 1328.58% | 564.79% | -31757.09% |
Debt / Equity | - | - | - | - | - | 3.35x | - | - | 0.60x | 0.68x |
Interest Coverage | -12.14x | -6.34x | -510.77x | -440.58x | - | -79.59x | -133.57x | 632.71x | -1038.38x | -403006.30x |
FCF Conversion | 0.69x | 0.49x | 0.84x | 0.64x | 0.81x | 0.80x | 0.81x | -0.84x | -12982.54x | 0.37x |
Revenue Growth | - | - | - | - | - | -24.6% | 550.4% | 22.15% | -97.63% | 1007.02% |
Related:PAVM Dividend History·PAVM Revenue History·PAVM Price History·PAVM P/E History·PAVM Financial Ratios·PAVM Institutional Holders
PAVM SEC Filings & Documents
PAVmed Inc. (PAVM) SEC filings — annual & quarterly reports (10-K, 10-Q)
PAVM Frequently Asked Questions
PAVmed Inc. (PAVM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
PAVmed Inc. (PAVM) reported $22.1M in revenue for fiscal year 2025.
PAVmed Inc. (PAVM) saw revenue decline by 97.6% over the past year.
PAVmed Inc. (PAVM) reported a net loss of $7.01B for fiscal year 2025.
Dividend & Returns
PAVmed Inc. (PAVM) has a return on equity (ROE) of 5.3%. This is below average, suggesting room for improvement.
PAVmed Inc. (PAVM) had negative free cash flow of $2.62B in fiscal year 2025, likely due to heavy capital investments.